Compositions for treating joint or connective tissue disease comprising dextran or poloxamer
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12576105-B2
Publication Date
2026-03-17
Expiration Date
Abstract
Disclosed is a composition for treating a joint disease or a connective tissue disease, a composition for cartilage regeneration, or a composition for treating an inflammatory disease, each of the compositions containing dextran, poloxamer or a mixture thereof. The composition stays in the joint or connective tissue for a long time due to the shock-absorbing effect, coating effect or anti-inflammation effect, relieves the shock, covers a damaged portion in a specific manner thereto, or reduces inflammation of an adhered portion. Thus, the composition may be useful for the treatment of the joint disease, the connective tissue disease, or for the cartilage regeneration.
Core Innovation
The invention provides a method of treating degenerative diseases of joints or connective tissue diseases by administering to a subject in need thereof a composition comprising a mixture of dextran and poloxamer. The dextran has an average molecular weight in a range of about 800 Da to about 1,200 Da, and the composition is described as a mixture rather than using the components separately.
The invention also provides a method of regenerating or protecting cartilage by administering to a subject in need thereof a composition comprising a mixture of dextran having an average molecular weight in a range of about 800 Da to about 1,200 Da and poloxamer. A long-lasting residence in the joint is proposed, with shock-absorbing, coating, and anti-inflammation effects, and optional inclusion of stem cells is described as part of the composition.
The document further describes treating inflammatory diseases by administering to a subject a composition comprising a mixture of dextran and poloxamer. In vitro data in an osteoarthritis model compare dextran/poloxamer single vs mixture, including cytotoxicity/proliferation and anti-inflammation measurements using IL-10/IL-6 expression ratio, and cartilage protection/regeneration readouts by modulating MMP-3 and MMP-13 expression while increasing type II collagen and aggrecan production.
Claims Coverage
The independent claims cover three distinct method categories: treating degenerative joint/connective tissue diseases, regenerating or protecting cartilage, and treating inflammatory diseases. Across these, the core inventive concept is administering a composition containing a dextran–poloxamer mixture with defined dextran molecular weight and poloxamer, with dependent claims adding concentration/range constraints and optional stem cells.
Treating degenerative disease of joints or connective tissue diseases with dextran–poloxamer mixture
A method comprising administering to a subject in need thereof a composition comprising a mixture of dextran having an average molecular weight in a range of about 800 Da to about 1,200 Da and poloxamer.
Regenerating or protecting cartilage with dextran–poloxamer mixture
A method comprising administering to a subject in need thereof a composition comprising a mixture of dextran having an average molecular weight in a range of about 800 Da to about 1,200 Da and poloxamer.
Treating inflammatory diseases with dextran–poloxamer mixture
A method comprising administering to a subject in need thereof a composition comprising a mixture of dextran having an average molecular weight in a range of 800 Da to 1,200 Da and poloxamer.
The claim set centers on administering dextran and poloxamer as a mixture where dextran is defined by an average molecular weight range of about 800 Da to about 1,200 Da, with claim refinements that constrain dextran/poloxamer concentration ranges and concentration ratios, restrict poloxamer variants, narrow inflammatory/connective tissue disease targets, and optionally add a stem cell.
Stated Advantages
Long-lasting residence in the joint is proposed via shock-absorbing (cushion) effect, coating effect, and anti-inflammation effect.
Reduced cytotoxicity/proliferation impact is described for mixtures compared with poloxamer 188 alone at high concentration.
Anti-inflammation is described via IL-10/IL-6 expression ratio.
Cartilage protection/regeneration is described by inhibiting MMP-3 and MMP-13 expression while increasing type II collagen and aggrecan production.
Documented Applications
Treating degenerative diseases of joints or connective tissue diseases in a subject in need thereof.
Regenerating or protecting cartilage in a subject in need thereof.
Treating inflammatory diseases in a subject in need thereof.
In vitro osteoarthritis model use with chondrocytes, including comparison of dextran/poloxamer single vs mixture and measurement of inflammation and cartilage-related markers.
Interested in licensing this patent?